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Abstract: The flavivirus genus includes viruses with a remarkable ability to produce disease 
on a large scale. The expansion and increased endemicity of dengue and West Nile viruses 
in the Americas exemplifies their medical and epidemiological importance. The rapid 
detection of viral infection and induction of the innate antiviral response are crucial to 
determining the outcome of infection. The intracellular pathogen receptors RIG-I and 
MDA5 play a central role in detecting flavivirus infections and initiating a robust antiviral 
response. Yet, these viruses are still capable of producing acute illness in humans. It is now 
clear that flaviviruses utilize a variety of mechanisms to modulate the interferon response. 
The non-structural proteins of the various flaviviruses reduce expression of interferon 
dependent genes by blocking phosphorylation, enhancing degradation or down-regulating 
expression of major components of the JAK/STAT pathway. Recent studies indicate that 
interferon modulation is an important factor in the development of severe flaviviral illness. 
This suggests that an increased understanding of viral-host interactions will facilitate the 
development of novel therapeutics to treat these viral infections and improved biological 
models to study flavivirus pathogenesis.  
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Abbreviations 
CARDIF   Caspase  recruitment  domain adaptor inducing IFN-β 
CARD     Caspase recruitment domains 
CNS      Central nervous system 
DCs     Dendritic  cells   
DENV     Dengue virus 
dsRNA  Double-stranded  RNA 
ER     Endoplasmic  reticulum 
IKK      Inhibitor of kappa kinase 
Iκβ     Inhibitor  of  NF-  κβ 
IL     Interleukin 
IFN-     Interferon 
IFN-AR   Interferon-α/β receptor 
IPS-1      Interferon-beta promoter stimulator 
IRAK      Interleukin (IL)-1 receptor–associated kinase 
IRF      Interferon regulatory factor 
ISGF      Interferon-stimulated gene factor 
ISGs      Interferon stimulated genes 
ISRE      Interferon-stimulated response element 
JAK     Janus  kinases 
JEV     Japanese  encephalitis  virus 
LC     Langerhans  dendritic  cells 
MAVS     Mitochondrial anti-viral signaling protein 
MDA5     Melanoma differentiation-associated gene 5 
MEFs      Mouse embryonic fibroblasts 
MyD88  Myeloid  differentiation  primary response gene (88) 
NEMO      Nuclear factor kappa B essential modifier 
NF-κβ     Nuclear Factor-Kappa Beta 
NS     Nonstructural 
PAMPs    Pathogen-associated molecular patterns 
PBMC'S    Peripheral blood mononuclear cells 
pDCs      Plasmacytoid dendritic cells 
PRRs     Pathogen-recognition  receptors 
RIG-I      Retinoic acid inducible gene I 
RIP1      Receptor interacting protein 1 
RLRs     RIG-1-like  receptors 
ssRNA     Single-stranded RNA 
STAT      Signal transducers and activators of transcription 
TBEV     Tick-borne encephalitis virus 
TBK1      TANK-binding kinase 1 
TIR     Toll/IL-1  receptor Viruses 2010, 2                  
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TLRs     Toll-like  receptors 
TNF      Tumor necrosis factor 
TRAF     TNF receptor associated factor family 
TRIF     TIR-domain-containing adaptor-inducing interferon-β 
Tyk     Tyrosine  kinase 
WNV      West Nile virus 
YFV      Yellow fever virus 
1. Detection of Flaviviruses by the Host Cell 
Mammalian cells utilize specialized cellular proteins termed pathogen-recognition receptors (PRRs) 
to sense invading pathogens. These proteins function by recognizing specific pathogen-associated 
molecular patterns (PAMPs) produced during the course of infection. Two classes of PRRs, the   
toll-like receptors (TLRs) and the retinoid-inducible gene I (RIG-I)-like receptors (RLRs), are essential 
for responding to viral infection [1]. The various PRRs recognize different viral structural and/or 
functional features; nonetheless, they all function to initiate signaling cascades that result in the 
activation of transcription factors critical for the onset of the type 1 interferon (IFN-α/β) response. 
Overexpression studies in vitro as well as targeted gene depletion in vivo suggest that both the TLR 
and RLR pathways play vital roles in detecting and responding to flavivirus infections (Figure 1). 
However, the specific PRRs involved in mediating the antiviral response are likely to be virus- and 
cell-type specific. 
2. Activation of RLR by Flaviviruses 
The RLR family members RIG-I and MDA5 are ubiquitous cytosolic proteins that mediate the 
host’s intracellular antiviral response to viral infection. These cytoplasmic receptors are essential for 
detecting RNA viruses in most cell types [2–5]. RIG-I and MDA5 both contain two N-terminal 
caspase recruitment domains (CARD) followed by a single DExD/H box RNA helicase domain. 
Binding of viral PAMPs to the helicase domain is postulated to induce conformational changes that 
allow these RLRs to interact with the downstream adaptor protein IPS-1/MAVS/CARDIF via their 
CARD domains. These interactions initiate a signaling cascade, resulting in the activation of 
transcription factors such as IRF-3, IRF-7 and NFκB, which are required for the induction of IFN- 
and the establishment of an antiviral state within the cell. Several groups have demonstrated that RIG-I 
preferentially recognizes single-stranded RNA (ssRNA) molecules containing free terminal   
5’ triphosphates [6–9]. However, a recent study by Kato et al. demonstrated that RIG-I and MDA5 
interact with double-stranded RNAs (dsRNA) in a length-dependent manner, regardless of 5’ end 
modifications [10]. Short dsRNA molecules were shown to bind to and activate RIG-I while long 
dsRNAs functioned solely as agonists of MDA5. These studies indicate that RIG-I recognizes the  
5’ triphosphates present on uncapped termini of viral genomes and dsRNA produced during the course 
of infection, while MDA5 recognizes long dsRNA viral genomes or long duplex RNAs produced 
during genome replication.  Viruses 2010, 2                  
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Figure 1. PRRs involved in detecting flaviviruses. Dashed line indicates cell type and/or 
context-dependent blockade of pathway.  
 
 
RIG-I has been shown to be involved in sensing every member of the flavivirus genus examined to 
date. Stimulation of the IFN-α⁄β promoter in response to Japanese encephalitis virus (JEV) infection 
was reduced in cells overexpressing a dominant negative form of RIG-I and was completely lacking in 
mouse embryo fibroblasts (MEFs) recovered from RIG-I
−/− mice [5,11]. Furthermore, RIG-I-deficient 
mice exhibit a marked decrease in serum IFN-α/β levels and an increased susceptibility to JEV 
compared to wild type control mice, while deletion of MDA5 has no affect [5]. This suggests that  
RIG-I, but not MDA5 signaling pathways are involved in initiating the antiviral response to JEV. In 
contrast, disruption of RIG-I signaling does not ablate the induction of antiviral programs in response 
to dengue Virus (DENV) and West Nile virus (WNV) infection [12–14]. In the case of WNV, the 
onset of the innate antiviral response was merely delayed in RIG-I
−/− cells compared to wild type 
controls. This suggests that the RIG-I pathway mediates the initial activation of the antiviral response 
to WNV, though distinct secondary pathways are also clearly involved. Nonetheless, WNV replication 
is enhanced in the absence of RIG-I, indicating that this pathway plays a critical role in constraining 
WNV. The fact that cells respond to WNV and DENV in the absence of RIG-I suggests that other 
PRRs are also involved in the detection of these viruses. Several lines of evidence indicate that MDA5 
functions as the secondary receptor for sensing both WNV and DENV. As with RIG-I-deficient cells, Viruses 2010, 2                  
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MDA5
−/− MEFs were shown to retain the ability to respond to WNV and DENV infection [12,14]. In 
addition, disruption of both the MDA5 and RIG-I signaling pathways abrogated the response to WNV 
and DENV, indicating that both viruses trigger RIG-I and MDA5-dependent responses [12,14]. This is 
further supported by the observation that IPS-1 null MEFs were refractory to WNV and   
DENV-mediated activation of IRF-3. Additionally, RIG-I and MDA5 expression is upregulated in 
WNV and DENV-infected MEFs as well as DENV-infected muscle satellite cells, monocytes, B cells 
and dendritic cells (DCs) [12,14]. Collectively, the evidence indicates that both RIG-I and MDA5 play 
important roles in initiating and sustaining the antiviral response to WNV and DENV. 
The role of the RLR system in controlling yellow fever virus (YFV) has yet to be examined. 
However, both RIG-I and MDA5 expression was upregulated in peripheral blood mononuclear cells 
(PBMCs) recovered from individuals vaccinated with YF-17D [15], suggesting a possible role for both 
of these PRRs in responding to YFV in vivo. Combined, these studies indicate that RIG-I is involved in 
sensing all flavivirus infections; however, MDA5’s role is virus-dependent.  
3. Activation of TLRs 
Members of the TLR family are evolutionarily conserved transmembrane molecules that are 
expressed on the cell surface or within endocytic vesicles in a cell type-dependent manner [2,16]. 
Expression of the various TLRs is typically restricted to specific subtypes of immune cells, suggesting 
that these receptors play distinct roles in triggering a response to an invading pathogen [17]. Detection 
of PAMPS is mediated by the leucine rich repeats located in the ectodomain of the TLR. Thus, TLRs 
are restricted to the detection of either extracellular or vesicle-bound PAMPs. Binding of extracellular 
ligands to the TLRs initiates a signal transduction cascade through a Toll/IL-1 receptor (TIR) 
homologous domain located in the cytoplasmic region of the protein. The adaptor protein MyD88 
mediates the signaling pathways of all TLRs except TLR3, which utilizes TIR-domain-containing 
adaptor-inducing interferon-β (TRIF) instead. Cellular localization of TLR3 and TLR7 is cell   
type-dependent. Human fibroblasts express TLR3 and TLR7 on the cell surface. However, these TLRs 
are localized to intracellular compartments of the endocytic pathway in cells of immune origin [2,16]. 
TLR3 and TLR7 function as a broad sensor of dsRNA and ssRNA, respectively. However, TLR7 
response to ssRNAs is enhanced by higher order structures within viral RNA [18-20]. As with the 
RLRs, stimulation of the TLR pathways results in a multivalent signaling cascade that leads to the 
production of IFN-α/β and inflammatory cytokines, which in turn stimulates maturation of DCs and 
the establishment of an antiviral response [21].  
The involvement of the various members of the TLR system appears to be virus dependent. Both 
TLR3 and TLR7 have been shown to be involved in sensing DENV and WNV. Silencing of TLR3 
expression in human monocyte cell lines altered cytokine production in response to DENV   
infection [22]. Additionally, overexpression of TLR3 enhanced cytokine production and inhibited 
DENV replication. This suggests that TLR3 may be an important component of the antiviral response 
to DENV. However, the observation that DENV infection failed to induce cytokine production in bone 
marrow-derived macrophages from MyD88 null mice suggests that additional TLRs are also involved 
in sensing this virus [23]. This is further supported by the fact that TLR7 specific inhibitors attenuated 
IFN-α/β production by plasmacytoid dendritic cells (pDCs) in response to DENV [20]. Furthermore, Viruses 2010, 2                  
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treatment of monocytes and DCs with bafilomycin A, a vacuolar H+-ATPase inhibitor, suppressed 
DENV-induced production of IFN-α⁄β and IL-8, indicating that endosomal acidification is necessary 
for the innate detection of this virus [20,22]. Since TLR7 signaling and viral entry into the cells require 
acidification of endocytic vesicles, it has been proposed that detection of DENV by TLR7 is coupled to 
viral fusion and uncoating [20].  
TLR3 and TLR7 have also been implicated in WNV infections [24–26], though the role of these 
TLRs in WNV-mediated pathogenesis remains controversial. Wang et al. observed that WNV 
virulence was attenuated in TLR3
−/− mice [24], despite increased viremia. The authors proposed that 
the enhanced virulence in wild type mice was due to an increase in the permeability of the blood-brain 
barrier caused by induction of an inflammatory response by TLR3. Therefore, stimulation of the TLR3 
pathway by WNV in vivo leads to increased pathogenesis rather than protection. In contrast, a recent 
study re-examining the pathogenesis of WNV in TLR3-deficient mice reported an increase in the 
susceptibility to WNV in these mice [25].  
It has also been demonstrated that mice deficient in either MyD88 or TLR7 exhibit increased 
viremia and enhanced susceptibility to WNV infection when challenged through an intraperitoneal 
route [24]. Additionally, WNV-infected TLR7-deficient mice exhibited increased systemic levels of 
the proinflammatory cytokines IFN-α, IFN-β, IL-6, IL-1b and TNF-α compared to wild type control 
mice. However, decreased levels of IL-12 p35 and IL-23 p19 were detected in the brain of TLR7
−/− 
mice infected with WNV. The reduction in IL-23 expression corresponds with a decrease in infiltration 
of peripheral immune cells into infected target organs in TLR7
−/− mice challenged with a lethal dose of 
WNV. This suggests that the reduced survival of WNV-infected TLR7
−/− mice is due to a diminished 
ability to trigger migration of the immune cells responsible for neutralizing and clearing the infection 
to the proper locations. 
More recently it has been suggested that TLR7 may in fact play a role in promoting WNV   
infection [26]. Reduced numbers of Langerhans dendritic cells (LC) were observed in the epidermis of 
wild type but not TLR7
−/− mice following cutaneous challenge with WNV. This suggests that the 
TLR7 response may stimulate LC migration to the draining lymph nodes, thereby counteracting the 
protective function of the TLR7 response by promoting dissemination of WNV to peripheral tissues. 
However, the survival rates of wild type and TLR7
−/− mice infected with WNV either intradermally or 
by infected mosquito feeding were not significantly different. These data suggest that both TLR7 and 
TLR3 contribute to the antiviral response to WNV, though the exact role of these pathways in WNV-
mediated pathogenesis remains to be determined. 
TLRs have also been implicated in the activation of DCs by YF-17D [27]. DCs recovered from 
MyD88, TLR2, TLR7 and TLR9 -deficient mice all exhibited reduced levels of cytokine production in 
response to YF-17D. In addition, human fibroblasts stably transfected with TLR8 and an NF-κB 
luciferase reporter responded more robustly to YF-17D, suggesting that this TLR8 is also capable of 
detecting the virus [27].  
Combined, these recent studies indicate that the TLR system plays a role in stimulating the antiviral 
response to YFV, DENV and WNV but not to JEV. TNF-α⁄β levels in JEV infected DCs were unaffected 
by ablation of MyD88 and more importantly depletion of MyD88 had no effect on susceptibility to 
JEV in vivo [5,23]. In sum, multiple PRR are clearly involved in the initiation of the antiviral response 
to most flaviviruses; however the pathways engaged during infection are virus dependent. Viruses 2010, 2                  
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4. Evasion of the Host Recognition 
The TLR and RLR signaling cascades converge at the point of activation of the latent transcription 
factors IRF-3 and NFκB. Activation of these transcription factors is critical for the rapid establishment 
of an antiviral state within the cell and induction of IFN-α⁄β. Many viruses induce activation of IRF-3 
within 3-6 h post-infection [28–32]. However, pathogenic strains of WNV fail to stimulate the IRF-3 
transcriptional activity until approximately 12-16 h post-infection, with maximal activation occurring 
much later [33]. This allows WNV to replicate to high levels prior to the induction and release of  
IFN-α⁄β, which provides two advantages to the virus. First, WNV is able to rapidly spread to 
neighboring uninfected cells, thereby outpacing the paracrine antiviral effects of IFN-α⁄β. Second, 
accumulation of viral proteins capable of attenuating the Janus kinase and signal transducers and 
activators of transcription (JAK/STAT) signal transduction pathway may render the infected cell 
refractory to the antiviral activity of IFN-α⁄β. The mechanism by which WNV avoids detection by 
PRRs early in infection remains to be determined. One possible explanation is that high levels of the 
WNV agonist(s) are required for efficient activation of IRF-3, such that activation does not occur until 
sufficient levels of the viral agonist(s) have accumulated. Alternatively, WNV may have evolved to 
specifically mask viral agonist(s) produced early in infection; thus blocking their accessibility to PRRs 
until the virus has established a productive infection. Additionally, expression of the WNV NS1 
protein individually or in the context of a replicon has been shown to impede TLR3-mediated 
activation of IRF-3 and NFκB in HeLa and 293 cells overexpressing TLR3. However, many cell lines 
infected with WNV remain responsive to soluble, intracellular and virally encoded forms of dsRNA 
ligands [13]. This suggests that the WNV NS1-imposed blockage of TLR3 may be cell type and/or 
context-dependent (Figure 1).  
Downstream of the PRRs, the transcription factor IRF-3 plays a pivotal role in controlling WNV 
replication and spread both in vitro and in vivo [34,35]. Mice lacking IRF-3 exhibited increased viral 
levels in the blood, peripheral organs and central nervous system (CNS). Furthermore, the absence of 
IRF-3 also resulted in an expanded tissue tropism, earlier entry into the CNS and ultimately increased 
susceptible to WNV infection. Yet, systemic levels of IFN-α/β in mice were unaffected by the ablation 
of IRF-3. This suggests that the protective effect of IRF-3 was due to antiviral actions of direct target 
genes. Indeed, macrophage and cortical neuronal cells derived from IRF-3 deficient mice confirmed 
that IRF-3 signaling triggers IFN-dependent and independent pathways important for controlling WNV 
replication. This suggests that WNV is sensitive to the antiviral actions of the IRF-3 pathway and that 
the ability to delay the activation of this arm of the host response may be central to WNV’s ability to 
achieve high levels of replication in vitro and in vivo [34,35].  
5. Suppression of the IFN-α/β Signaling by Flaviviruses 
Activation of the transcription factors IRF-3, IRF-7 and NF-κB through either the TLR or RLR 
systems results in the production of IFN-α/β, which is essential for the amplification of the response to 
the invading flaviviruses. Binding of secreted IFN-α/β to the IFN-α/β receptor on the surface of 
infected cells triggers the activation of the JAK/STAT signal transduction pathway. This in turn results 
in the stimulation of hundreds of promoters containing IFN-α/β-stimulated regulatory elements (ISRE), Viruses 2010, 2                  
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thus driving the expression of the wide variety of interferon stimulated genes (ISGs) that are 
responsible for establishing the antiviral state within the cell [36,37]. 
Accumulating evidence suggests that IFN-α/β has the potential to play an important role in 
inhibiting flavivirus replication. Pretreatment of human hepatoma cells with IFN-α/β results in 
inhibition of DENV replication. This inhibition is retained even when DENV RNA is transfected 
directly into cells, indicating that IFN-α/β affects post-entry steps of viral replication [38]. Likewise, 
WNV has been shown to be sensitive to antiviral effects of IFN-α/β in vitro [39–43]. Pretreatment of 
human and mouse cells with IFN-α/β inhibited WNV replication, though the magnitude of the 
sensitivity of WNV to IFN-α/β was cell line and strain-dependent [39,40,42].  
The importance of the IFN-α⁄β pathway in controlling flavivirus infection has also been 
demonstrated in vivo. Ablation of the IFN-α/β receptor or the JAK/STAT signaling pathway increased 
susceptibility to DENV, WNV and JEV infection [40,43–47]. While IFN pretreatment protected 
animals against lethal challenges with WNV and St. Louis encephalitis virus [48].  
DENV and WNV infections have been shown to induce the IFN-α/β response both in vitro and in 
vivo. Global and targeted gene expression profiling using various cell lines confirms the upregulation 
of IFN-α/β as well as downstream ISGs in response to either DENV or WNV infection [14,35,49–51]. 
Induction of IFN-α⁄β has also been detected in mice infected with WNV [25,34,43,52]. Additionally, 
high levels of IFN-α/β are present for long periods of time in pediatric dengue patients after 
defervescence; and differential global gene expression profiling has shown that key mediators of the 
IFN-dependent antiviral response are upregulated in patients [49,53–55].  
However, WNV and DENV are still capable of establishing productive infections despite the host’s 
ability to stimulate a robust IFN-α/β response to these viruses. Recent evidence suggests that severe 
disease associated with DENV and WNV infections correlates with their ability to counteract the   
IFN-α/β response [40]. The highest amounts of IFN-α/β detected in acutely ill dengue patients occur 
very early in infection, with IFN-α/β levels decreasing with disease progression [56]. Furthermore, 
DENV infection has been demonstrated to stimulate maturation of infected DCs and uninfected 
bystander cells, which leads to a robust induction of IFN-α/β, TNFα and significant pro-inflammatory 
cytokines [57,58]. However, the activation of infected DCs was blunted compared to uninfected cells. 
These findings suggest that DENV blocks or circumvents the IFN-α/β response. Thus, allowing the 
virus to propagate in the presence of IFN-α/β levels that would otherwise be a sufficient to impair its 
replication. The first experimental confirmation of DENV’s ability to block the IFN-α/β response was 
provided by Diamond and Harris [38], who demonstrated that a short incubation of cells with IFN-α/β 
prior to infection was required to completely inhibit viral replication. Additionally, DENV-encoded 
proteins are directly implicated in IFN-α/β antagonistic functions. The DENV-encoded proteins NS2A, 
NS4A and NS4B, expressed separately in human alveolar basal epithelial cells (A549), enhanced 
replication of IFN-α/β-sensitive viruses in the presence of IFN-α/β, and NS4B strongly inhibited   
IFN-α/β stimulation of ISRE promoter [59]. Co-expression of NS2A, NS4A and NS4B completely 
ablated IFN-α/β signaling, suggesting that these three proteins have a synergistic inhibitory effect on 
the JAK/STAT signaling pathway [59,60]. 
Co-transfection of NS4A/B together with NS2B/3 resulted in the cleavage of NS4A and NS4B and 
levels of IFN-α/β inhibition comparable to those obtained by co-transfection of the individual NS4A 
and NS4B proteins, indicating that the proteolytic processing of the NS4A/B region is needed for  Viruses 2010, 2                  
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anti-interferon function [59]. Correct targeting of NS4B to the ER is also required for its anti-
interferon activity, as deletion of the 2K segment without replacement by another signal peptide 
resulted in impairment of IFN-antagonistic function [60]. Additionally, transfection experiments show 
that cytoplasmic segments between the first and second transmembrane regions of NS4B are required 
for IFN-α/β antagonism. These experiments indicate that non-structural protein segments of DENV 
interact with components of the IFN-α/β pathway [59,61,62]; however, such interactions remain to be 
more precisely defined. The ability of NS4B to impair JAK/STAT signaling in Vero cells is conserved 
in both YFV and WNV, possibly indicating a consensus mechanism to block this pathway in 
mosquito-borne flaviviruses [40,41,60,63]. Indeed, both DENV and WNV have been shown to block 
JAK/STAT signaling by disrupting phosphorylation of STAT-1 (Figure 2) [40,41,60,63]. 
Figure 2. Suppression of the IFN-α/β signaling by flaviviruses. 
 
 
Recent evidence suggests that DENV encodes additional mechanisms to block IFN-α/β. STAT2 
levels were shown to be reduced in K562 (human chronic myeloid leukemia) and THP-1 (human 
monocytic) cell lines stably transfected with DENV replicons expressing all DENV non-structural 
proteins [64]. Furthermore, the reduction in STAT2 expression was shown to be due to NS5-mediated 
degradation [65,66]. As with NS4B, appropriate folding and posttranslational cleavage steps of NS5 
are required for antagonism of the IFN-α/β pathway. While DENV NS5 alone is capable of binding 
STAT2, its ability to target STAT2 for degradation requires the presence of a protease cleavage signal 
upstream of the N terminus of
 NS5;
 thus mirroring the NS5 processing that occurs in the context of the
 
DENV polyprotein during a natural infection [65]. Reduced levels of STAT2 and inhibition of STAT1 Viruses 2010, 2                  
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phosphorylation have also been correlated with the down-regulation of Tyk2 [67,68]. This places the 
interactions between DENV non-structural proteins and the IFN-α/β system in upstream components 
of the JAK/STAT signaling pathway. Given that DENV NS5 binds STAT2, it is tempting to   
speculate that NS4B may be involved in Tyk2 down-regulation; however, this remains to be 
experimentally confirmed.  
Unlike DENV, expression
 of JEV or Tick-borne encephalitis virus (TBEV) NS5 alone is sufficient
 
to inhibit IFN and mimic the effect observed with JEV or TBEV infection [69]. The inhibition of IFN 
signaling by JEV and TBEV NS5 homologues does not
 involve binding to the STATs but rather 
upstream events in the IFN pathways. In the case of tick-borne flaviviruses, the minimal requirement 
for this function has been ascribed to residues in two noncontiguous sequences of the RNA-dependent 
RNA polymerase region of NS5, which appears to come together in the tridimensional structure of this 
protein. Whether the
 expression of these proteins in the context of a cleaved precursor
 would confer 
additional functions has not been examined. Indeed, the NS5 protein of Kunjin virus, an Australian 
substrain of WNV, requires expression
 within the context of the NS1-5 region for efficient trans-
complementation
 of a self replicating Kunjin minigenome [70]. Expression of the Kunjin NS5 protein 
alone results in a
 100-fold decrease in replication activity, suggesting that appropriate cleavage of NS5 
is required in order to achieve optimal catalytic activity. This raises the possibility that other flaviviral 
proteins may also require proper cleavage in order to display their full anti-interferon functions.  
Viruses often encode complex, redundant mechanisms to antagonize the antiviral response of the 
host. Many viruses circumvent the IFN-α/β response by preventing the expression of IFN. Hepatitis C 
virus blocks IFN-α/β production by cleaving the cytoplasmic domain of the RLR signaling adaptor 
molecule IPS-1. As a consequence, IPS-1 loses its essential association to the mitochondria, which 
precludes effective binding with RIG-I and MDA5 and thereby abolishes RLR-mediated induction of 
IFN expression [71,72]. Although inhibition of IFN-α/β expression by DENV proteins has not been 
observed, this possibility cannot be ruled out. The blocking of IFN-α/β signaling, and not IFN-α/β 
expression, is supported by the fact that DENV NS4B protein specifically blocks signaling through the 
JAK/STAT pathway [60]. However, the IFN response undergoes auto-amplification as an infection 
progresses, and inhibition of the IFN-α/β signaling will in itself result in reduced IFN-α/β production. 
For example, TLRs and RLRs expression is upregulated by IFN-α/β. Therefore inhibition of the 
JAK/STAT pathway renders the cell less responsive to viral infection, and in so doing it reduces the 
expression of IFN-α/β. Further investigation will more precisely elucidate the extent to which the IFN-
α/β network is antagonized by DENV. On the other hand, Kunjin virus has been shown to regulate the 
expression of IFN-α/β. A single amino acid substitution in the NS2A protein of a Kunjin virus resulted 
in increased levels of IFN-α/β expression both in vitro and in vivo and a corresponding decrease in 
virulence in mice [73]. However, the mechanism by which the NS2A protein of Kunjin virus controls 
the level of IFN-α/β expression remains to be determined. 
6. Conclusions 
The TLR and RLR systems combat invading pathogens by (1) reprogramming the cell’s gene 
expression profile to establish an antiviral state and (2) inducing the expression of pro-inflammatory 
and antiviral cytokines in order to limit the viral spread. However, viruses have evolved multiple Viruses 2010, 2                  
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processes to escape the innate antiviral response. In case of flaviviruses, we are just beginning to 
recognize how intricate and redundant these mechanisms are. The flaviviral non-structural proteins 
clearly play an important role in attenuating signaling through the JAK/STAT pathway. However, 
there is much still to learn about the race between flavivirus replication and the antiviral response at 
the molecular level. Further studies will be required to tease apart the viral-host interacts that 
ultimately determine the disease outcome.  
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